niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer
Published 1 year ago • 3.3K plays • Length 2:59Download video MP4
Download video MP3
Similar videos
-
2:13
head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic crpc
-
5:46
metastatic castration-resistant prostate cancer – new learnings and perspectives
-
1:53
abiraterone vs docetaxel for metastatic castrate resistant prostate cancer
-
5:12
magnitude shows benefit of add-on niraparib for mutated mcrpc | gerhardt attard
-
1:34
dr. chi on abiraterone versus enzalutamide for metastatic castration-resistant prostate cancer
-
2:05
abiraterone in metastatic castration-sensitive prostate cancer
-
1:30
bmi and clinical outcomes in patients with metastatic castration-resistant prostate cancer
-
4:46
quality of life and new therapeutic options for metastatic castration-resistant prostate cancer
-
1:35
parp inhibitors for the treatment of metastic castration-resistant prostate cancer
-
0:21
akeega (abiraterone acetate and niraparib) tablets #shorts
-
1:06
imaagen: phase 2 trial of abiraterone acetate for advanced prostate cancer
-
1:33
fih study of arv-110 in metastatic castrate-resistant prostate cancer
-
2:27
triplet therapy for metastatic hormone-sensitive prostate cancer
-
6:41
esmo expert report on combination therapy in advanced prostate cancer @ asco gu 2022
-
4:34
card: cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer
-
2:16
testing the validity of a prognostic model for castration-resistant prostate cancer
-
3:48
olaparib zytiga for metastatic castrate-resistant prostate cancer | learn about clinical trials
-
11:51
expert video report on castration sensitive and resistant prostate cancer - 2021 asco annual meeting
-
1:10
abiraterone: a new therapy for metastatic prostate cancer | memorial sloan kettering